Drug:
Reaction: DISEASE PROGRESSION
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26940176 |
EU |
77 | 2 |
Hepatotoxicity, Gastrointestinal disorder, Disease progression, |
||||
NINTEDANIB, NINTEDANIB, |
||||
| 2 | 26940193 |
MY |
||
Disease progression, |
||||
GLOFITAMAB, |
||||
| 3 | 26941074 |
LB |
2 | |
Disease progression, |
||||
ATEZOLIZUMAB, PEGINTERFERON ALFA-2A, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 4 | 26941232 |
CN |
52 | 2 |
Disease progression, |
||||
LENVATINIB, |
||||
| 5 | 26942008 |
EU |
9 | 1 |
Necrosis, Disease progression, Off label use, |
||||
MELPHALAN HYDROCHLORIDE, MELPHALAN, CARBOPLATIN, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DACTINOMYCIN, |
||||
| 6 | 26942417 |
US |
86 | 2 |
Disease progression, |
||||
LENALIDOMIDE, |
||||
| 7 | 26943003 |
BR |
24 | |
Liver injury, Skeletal injury, Disease progression, Paronychia, Alopecia, |
||||
PEMIGATINIB, PANTOPRAZOLE, |
||||
| 8 | 26943496 |
51 | 1 | |
Disease progression, Off label use, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 9 | 26943729 |
8 | ||
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 10 | 26943734 |
2 | ||
Disease progression, |
||||
| 11 | 26943735 |
56 | 2 | |
Disease progression, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 12 | 26943736 |
2 | ||
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 13 | 26943737 |
8 | ||
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 14 | 26944136 |
EU |
71 | 1 |
Disease progression, |
||||
VENETOCLAX, LINEZOLID, MOXIFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, DUTASTERIDE, GENTAMICIN, GENTAMICIN SULFATE, |
||||
| 15 | 26944248 |
2 | ||
Disease progression, Off label use, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 16 | 26944523 |
2 | ||
Disease progression, Haematotoxicity, Pneumonia, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 17 | 26945006 |
US |
75 | |
Hepatic cirrhosis, Disease progression, Metabolic dysfunction-associated steatohepatitis, Hepatic steatosis, |
||||
RESMETIROM, RESMETIROM, TRIAMTERENE CAPSULES, TRIAMTERENE, DULOXETINE HYDROCHLORIDE, DULOXETINE, SILODOSIN, FEXOFENADINE HYDROCHLORIDE, ALBUTEROL SULFATE, DENOSUMAB, ORAL SEMAGLUTIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, LOSARTAN POTASSIUM, LOSARTAN, GABAPENTIN, FLUTICASONE PROPIONATE, FLUOXETINE HYDROCHLORIDE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, COLESTIPOL HYDROCHLORIDE, ATENOLOL, ALLOPURINOL, |
||||
| 18 | 26947632 |
EU |
59 | |
Chronic graft versus host disease in lung, Interstitial lung disease, Disease progression, Off label use, |
||||
RUXOLITINIB, RUXOLITINIB, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, METHYLPREDNISOLONE, METHYLPREDNISOLONE, MONTELUKAST, MONTELUKAST, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, NINTEDANIB, NINTEDANIB, ENTECAVIR, ENTECAVIR ANHYDROUS, |
||||
| 19 | 26948014 |
CA |
||
Crohn^s disease, Disease progression, Drug ineffective, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, FOLIC ACID, METHOTREXATE, METHOTREXATE SODIUM, PREDNISONE, |
||||
| 20 | 26951155 |
50 | 1 | |
Disease progression, |
||||
CABOZANTINIB, CABOZANTINIB, FERROUS SULFATE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDICAINE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, OXYCODONE, METHYLPHENIDATE HYDROCHLORIDE, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, |
||||
| 21 | 26934385 |
CN |
57 | 2 |
Disease progression, Drug ineffective, |
||||
ZANUBRUTINIB, ZANUBRUTINIB, RITUXIMAB, ETOPOSIDE, |
||||
| 22 | 26934633 |
US |
||
Disease progression, |
||||
TECLISTAMAB-CQYV, |
||||
| 23 | 26934648 |
PK |
56 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 24 | 26934778 |
US |
1 | |
Disease progression, |
||||
EDARAVONE, EDARAVONE, |
||||
| 25 | 26935201 |
EU |
||
Hemiparesis, Spinal muscular atrophy, Disease progression, Areflexia, Motor dysfunction, |
||||
ONASEMNOGENE ABEPARVOVEC-XIOI, |
||||
| 26 | 26935224 |
US |
1 | |
Duchenne muscular dystrophy, Disease progression, Fall, |
||||
VAMOROLONE, VAMOROLONE, PREDNISONE, |
||||
| 27 | 26935277 |
13 | 1 | |
Disease progression, Off label use, |
||||
HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 28 | 26935456 |
PK |
62 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 29 | 26935642 |
AU |
63 | 2 |
Hepatotoxicity, Haemolytic anaemia, Pneumonitis, Disease progression, Hypertransaminasaemia, Pyrexia, Off label use, |
||||
PEMETREXED, PEMETREXED DISODIUM, BEVACIZUMAB, BRIGATINIB, LORLATINIB, |
||||
| 30 | 26936075 |
MX |
78 | 1 |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 31 | 26936504 |
GB |
62 | |
Disease progression, |
||||
BREXUCABTAGENE AUTOLEUCEL, |
||||
| 32 | 26936627 |
EU |
12 | 1 |
Necrosis, Disease progression, |
||||
MELPHALAN HYDROCHLORIDE, MELPHALAN, CARBOPLATIN, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DACTINOMYCIN, |
||||
| 33 | 26937186 |
EU |
43 | 1 |
Hodgkin^s disease refractory, Platelet count abnormal, Blood lactate dehydrogenase abnormal, Haemoglobin abnormal, C-reactive protein abnormal, Pyrexia, White blood cell count abnormal, Product use issue, Haematopoietic stem cell mobilisation, Haematopoietic stem cell mobilisation, Disease progression, Nephropathy toxic, Night sweats, |
||||
PEMBROLIZUMAB, VINCRISTINE SULFATE, VINCRISTINE SULFATE, LORATADINE, LORATADINE ORAL, VINORELBINE, CISPLATIN, PREDNISONE, PREDNISONE, CYTARABINE, CYTARABINE, OXALIPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ETOPOSIDE, BRENTUXIMAB VEDOTIN, GENTAMICIN, GENTAMICIN SULFATE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, PREDNISONE, VINORELBINE, |
||||
| 34 | 26937251 |
GB |
2 | |
Immunosuppression, Disease progression, |
||||
POSACONAZOLE, POSACONAZOLE DELAYED-RELEASE, FINGOLIMOD HCL, FINGOLIMOD, FINGOLIMOD HYDROCHLORIDE, |
||||
| 35 | 26937255 |
LB |
2 | |
Disease progression, Off label use, |
||||
ATEZOLIZUMAB, PEGINTERFERON ALFA-2A, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 36 | 26937899 |
US |
61 | 2 |
Product ineffective for unapproved use, Disease progression, Fatigue, Product prescribing issue, |
||||
ETOPOSIDE, ETOPOSIDE, ATEZOLIZUMAB, ATEZOLIZUMAB, CARBOPLATIN, CARBOPLATIN, |
||||
| 37 | 26938557 |
IN |
53 | 1 |
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 38 | 26931123 |
IN |
63 | 2 |
Vascular device infection, Off label use, Cough, Fatigue, Disease progression, |
||||
ATEZOLIZUMAB, ATEZOLIZUMAB, |
||||
| 39 | 26931223 |
65 | 2 | |
Dehydration, Disease progression, Nausea, Vomiting, Diarrhoea, Rash pruritic, Drug ineffective, |
||||
DATOPOTAMAB DERUXTECAN, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 40 | 26931922 |
US |
70 | 2 |
Disease progression, |
||||
FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, OXALIPLATIN, OXALIPLATIN, BEVACIZUMAB, BEVACIZUMAB, ENCORAFENIB, ENCORAFENIB, |
||||
| 41 | 26932127 |
CA |
79 | 2 |
Disease progression, |
||||
VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, APIXABAN, POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL (3350), POLYETHYLENE GLYCOL 400, INSTALAX POLYETHYLENE GLYCOL 3350, SENNOSIDES, DIMENHYDRINATE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, LORATADINE, LORATADINE ORAL, FLUCONAZOLE, FLUCONAZOLE, FLUCONAZOLE, PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 42 | 26932135 |
CA |
68 | 1 |
Disease progression, |
||||
VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL (3350), POLYETHYLENE GLYCOL 400, INSTALAX POLYETHYLENE GLYCOL 3350, SENNOSIDES, THIAMINE HYDROCHLORIDE, ALLOPURINOL, ALLOPURINOL, ALLOPURINOL, FUROSEMIDE, CALCIUM, DICLOFENAC, DICLOFENAC SODIUM, CITALOPRAM, CITALOPRAM HYDROBROMIDE, ERGOCALCIFEROL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, NICOTINE POLACRILEX, NICOTINE, NICOTINE POLACRILEX MINI, NICOTINE POLARILEX, FLUCONAZOLE, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, |
||||
| 43 | 26932461 |
TR |
||
Disease progression, Chest pain, |
||||
ATEZOLIZUMAB, |
||||
| 44 | 26932826 |
CN |
67 | 2 |
Disease progression, |
||||
POLATUZUMAB VEDOTIN, |
||||
| 45 | 26932844 |
EU |
45 | |
Disease progression, Off label use, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, GLOFITAMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, BENDAMUSTINE HCL, LONCASTUXIMAB TESIRINE, |
||||
| 46 | 26932858 |
RU |
49 | |
Disease progression, |
||||
OBINUTUZUMAB, OBINUTUZUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, CISPLATIN, |
||||
| 47 | 26933019 |
RU |
67 | |
Disease progression, Oesophageal compression, Dysphagia, Pharyngeal disorder, Death, |
||||
OBINUTUZUMAB, BENDAMUSTINE HCL, |
||||
| 48 | 26933336 |
US |
48 | 2 |
Osteonecrosis of jaw, Infection, Disease progression, |
||||
ZOLEDRONIC ACID, |
||||
| 49 | 26933637 |
AU |
||
Disease progression, |
||||
BREXUCABTAGENE AUTOLEUCEL, |
||||
| 50 | 26926631 |
JP |
||
Drug ineffective, Disease progression, |
||||
LUSPATERCEPT, |
||||
| 51 | 26927016 |
US |
2 | |
Disease progression, |
||||
INAVOLISIB, |
||||
| 52 | 26927278 |
US |
77 | 1 |
Disease progression, Off label use, |
||||
POMALIDOMIDE, |
||||
| 53 | 26927523 |
CN |
80 | 1 |
Disease progression, Bronchopulmonary aspergillosis, Hallucination, visual, Tremor, Discomfort, |
||||
ISAVUCONAZONIUM SULFATE, ISAVUCONAZONIUM SULFATE, VORICONAZOLE, VORICONAZOLE INJECTION, |
||||
| 54 | 26927583 |
EU |
59 | 1 |
Chronic graft versus host disease in lung, Interstitial lung disease, Disease progression, Off label use, |
||||
AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, MONTELUKAST, MONTELUKAST, RUXOLITINIB, RUXOLITINIB, METHYLPREDNISOLONE, METHYLPREDNISOLONE, NINTEDANIB, NINTEDANIB, ENTECAVIR, ENTECAVIR ANHYDROUS, |
||||
| 55 | 26928147 |
HK |
||
Disease progression, |
||||
GILTERITINIB, |
||||
| 56 | 26928547 |
HK |
||
Disease progression, |
||||
GILTERITINIB, VENETOCLAX, |
||||
| 57 | 26928687 |
68 | 1 | |
Disease progression, Off label use, |
||||
AMPICILLIN SODIUM AND SULBACTAM SODIUM, AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM AND SULBACTAM SODIUM, AMPICILLIN AND SULBACTAM, DAPTOMYCIN, DAPTOMYCIN, CEFTRIAXONE, CEFTRIAXONE SODIUM, MEROPENEM, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, LANSOPRAZOLE, CARVEDILOL, CALCIUM CARBONATE, ANTACID, |
||||
| 58 | 26928913 |
US |
52 | 1 |
Drug ineffective, Disease progression, |
||||
PREDNISONE, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, |
||||
| 59 | 26929047 |
TZ |
45 | 1 |
Disease progression, |
||||
PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, METHYLPREDNISOLONE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 60 | 26929834 |
JP |
2 | |
Metastases to meninges, Disease progression, Hypoaesthesia, |
||||
OSIMERTINIB, |
||||
| 61 | 26929845 |
US |
54 | 2 |
Disease progression, Drug ineffective, |
||||
ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, ANASTROZOLE, ANASTROZOLE TABLETS, ANASTROZOLE, ANASTROZOLE TABLETS, ANASTROZOLE, ANASTROZOLE TABLETS, ANASTROZOLE, ANASTROZOLE TABLETS, |
||||
| 62 | 26930508 |
7 | 1 | |
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 63 | 26930509 |
7 | 1 | |
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 64 | 26930510 |
7 | 2 | |
Disease progression, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 65 | 26930512 |
7 | ||
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 66 | 26930513 |
2 | ||
Death, Disease progression, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 67 | 26930786 |
|||
Disease progression, Central nervous system lesion, |
||||
TERIFLUNOMIDE, |
||||
| 68 | 26930901 |
US |
57 | 1 |
Death, Disease progression, Deafness unilateral, Fatigue, Decreased appetite, Dizziness, Fall, Injury, |
||||
DORDAVIPRONE, LEVETIRACETAM, INSULIN GLARGINE, ATORVASTATIN CALCIUM, MECLIZINE HYDROCHLORIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 69 | 26930989 |
RU |
65 | 2 |
Pseudomembranous colitis, Intestinal haemorrhage, Disease progression, |
||||
POLATUZUMAB VEDOTIN, RITUXIMAB, PREDNISONE, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, OXALIPLATIN, ETOPOSIDE PHOSPHATE, |
||||
| 70 | 26931016 |
2 | ||
Disease progression, Intestinal obstruction, Gastrointestinal toxicity, Asthenia, |
||||
CAPECITABINE, CAPECITABINE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DULOXETINE HYDROCHLORIDE, DULOXETINE, FAMOTIDINE, NITROGLYCERIN, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OXYCODONE, |
||||
| 71 | 26921479 |
EU |
68 | |
Vaginal cancer, Disease progression, |
||||
CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PEMBROLIZUMAB, BEVACIZUMAB, |
||||
| 72 | 26921660 |
EU |
65 | 1 |
Cardio-respiratory arrest, Malignant neoplasm oligoprogression, Metastases to bone, Pneumonia, Metastases to liver, Anaemia, Disease progression, Haemoptysis, Weight decreased, Bone disorder, Upper respiratory tract infection, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, |
||||
| 73 | 26922254 |
EU |
28 | 1 |
Disease progression, Anaemia, Drug ineffective, |
||||
DASATINIB, ASCIMINIB, NILOTINIB, |
||||
| 74 | 26922485 |
CA |
63 | 1 |
Disease progression, |
||||
VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ATENOLOL, RAMIPRIL, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, PREDNISONE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, EPINEPHRINE, ADRENALINUM, FENTANYL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PHENYLEPHRINE, PROPOFOL, CEFAZOLIN SODIUM, CEFAZOLIN, ALLOPURINOL, FLUCONAZOLE, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, PENICILLIN V POTASSIUM, HYDROXYUREA, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, TIMOLOL, |
||||
| 75 | 26922873 |
HK |
9 | 2 |
Drug-induced liver injury, Disease progression, Cranial nerve paralysis, |
||||
IMIPENEM AND CILASTATIN SODIUM, IMIPENEM AND CILASTATIN, CEFTAZIDIME, TIGECYCLINE, AMIKACIN, LINEZOLID, RIFABUTIN, CLOFAZIMINE, |
||||
| 76 | 26923181 |
BR |
2 | |
Drug intolerance, Immunodeficiency, Epistaxis, Loss of consciousness, Haemangioma rupture, Liver injury, Spinal cord disorder, Spinal cord injury, Metastases to spine, Metastases to bone, Metastasis, Metastases to bone, Metastases to liver, Immunodeficiency, Face injury, Skin exfoliation, Dry throat, Alopecia, Erythema, Dry skin, Vulvovaginal dryness, Vulvovaginal discomfort, Vulvovaginal burning sensation, Nasal dryness, Skin disorder, Pruritus, Neoplasm, Gait disturbance, Tumour marker increased, Reflux gastritis, Discouragement, Visual impairment, Greater trochanteric pain syndrome, Feeding disorder, Haemangioma, Disease progression, Weight decreased, Illness, Aphthous ulcer, Oral herpes, Swelling of eyelid, Sinusitis, Rhinitis, Rhinitis allergic, Eyelid sensory disorder, Vein disorder, Frostbite, Ocular hyperaemia, Haemorrhoids, Hair texture abnormal, Trichorrhexis, Eyelid ptosis, Rectocele, Gastrointestinal disorder, Hiatus hernia, Nasal pruritus, Dry eye, Head discomfort, PIK3CA-activated mutation, Swelling, Abdominal discomfort, Head injury, Nasal injury, Skin lesion, Wound, Injury, Oestrogen deficiency, Drug ineffective, Panic disorder, Nasal discomfort, Haematoma, Asthenopia, Hypermetropia, Astigmatism, Petechiae, Dyspnoea, Skeletal injury, Phlebitis, Oral pain, Nasal disorder, Eye swelling, Anosmia, Movement disorder, Pain, Vulvovaginal exfoliation, Chills, Paraesthesia, White blood cell count decreased, Neutrophil count decreased, Pyrexia, Fatigue, Constipation, Dry mouth, Application site bruise, Application site pain, Ear disorder, Urinary tract infection, Skin atrophy, Lip dry, Pain, Pain in extremity, Bone pain, Dysstasia, Application site swelling, Arthralgia, Insomnia, Malaise, Product availability issue, |
||||
FULVESTRANT, ANASTROZOLE, ANASTROZOLE TABLETS, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, FULVESTRANT, FULVESTRANT, FULVESTRANT, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, ERGOCALCIFEROL, ACONITUM NAPELLUS, BRYONIA ALBA, EUPATORIUM PERFOLIATUM, FERRUM PHOSPHORICUM, GELSEMIUM SEMPERVIRENS, KALI BICHROMICUM, KALI LODATUM, ZINCUM GLUCONICUM., DEXTROMETHORPHAN HBR, GUAIFENESIN, PHENYLEPHRINE HCL, ACONITUM NAPELLUS, ALLIUM CEPA, GELSEMIUM SEMP., ZINCUM GLUCONICUM, BAPTISIA TINCTORIA, ECHINACEA ANGUSTIFOLIA, EUPATORIUM PERFOLIATUM, LOMATIUM DISSECTUM, PUERARIA LOBATA, TRIFOLIUM PRATENSE, PHYTOLACCA DECANDRA, ALLIUM CEPA, ARSENICUM IODATUM, BARYTA CARBONICA, BROMIUM, CALCAREA CARBONICA, KALI MURIATICUM, LACHESIS MUTUS, MERCURIUS SOLUBILIS, SILICEA, ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL, |
||||
| 77 | 26923575 |
ID |
||
Breast cancer metastatic, Disease progression, Off label use, |
||||
TRASTUZUMAB, TRASTUZUMAB, ADO-TRASTUZUMAB EMTANSINE, EXEMESTANE, |
||||
| 78 | 26924203 |
EU |
58 | |
Vaginal cancer, Disease progression, |
||||
CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 79 | 26924303 |
EU |
45 | 1 |
Disease progression, Off label use, |
||||
DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, GLOFITAMAB, GLOFITAMAB, GLOFITAMAB, GLOFITAMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, BENDAMUSTINE HCL, BENDAMUSTINE HCL, BENDAMUSTINE HCL, BENDAMUSTINE HCL, LONCASTUXIMAB TESIRINE, LONCASTUXIMAB TESIRINE, LONCASTUXIMAB TESIRINE, LONCASTUXIMAB TESIRINE, |
||||
| 80 | 26924606 |
TR |
||
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 81 | 26924703 |
EU |
74 | 2 |
Disease progression, |
||||
LENALIDOMIDE, LENALIDOMIDE, |
||||
| 82 | 26924836 |
US |
53 | |
Mouth haemorrhage, Melaena, Myelofibrosis, Gingival bleeding, Body temperature increased, Abdominal pain upper, Vomiting, Night sweats, Pruritus, Hepatic cyst, Bladder hypertrophy, Disease progression, Haemoglobin decreased, Platelet count decreased, Contusion, Nausea, Headache, Dyspnoea exertional, |
||||
RUXOLITINIB, RUXOLITINIB, |
||||
| 83 | 26925018 |
AR |
50 | |
Disease progression, Hyperbilirubinaemia, |
||||
LENALIDOMIDE, |
||||
| 84 | 26925328 |
61 | 2 | |
Disease progression, Oral pigmentation, Stomatitis, Periodontal disease, Taste disorder, |
||||
DATOPOTAMAB DERUXTECAN, DATOPOTAMAB DERUXTECAN, DATOPOTAMAB DERUXTECAN, DENOSUMAB, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, MAGNESIUM OXIDE, DEXAMETHASONE SODIUM PHOSPHATE, |
||||
| 85 | 26925330 |
6 | 2 | |
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 86 | 26925366 |
57 | 2 | |
Disease progression, Interstitial lung disease, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 87 | 26925446 |
2 | ||
Disease progression, Metastases to lung, Haematotoxicity, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 88 | 26925711 |
55 | 2 | |
Dizziness, Gait disturbance, Headache, Mental status changes, Respiratory failure, Disease progression, Cerebral ventricle dilatation, |
||||
ETOMIDATE, ETOMIDATE INJECTION, FENTANYL, LEVETIRACETAM, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, PROPOFOL, TOCILIZUMAB, TEMAZEPAM, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, TAZOBACTAM SODIUM AND PIPERACILLIN SODIUM, PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, |
||||
| 89 | 26925819 |
EU |
31 | 1 |
Disease progression, |
||||
PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, RAMUCIRUMAB, RAMUCIRUMAB, RAMUCIRUMAB, RAMUCIRUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 90 | 26926076 |
TZ |
45 | |
Disease progression, |
||||
CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 91 | 26926080 |
RU |
1 | |
Disease progression, |
||||
DOXORUBICIN, CISPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ETOPOSIDE, |
||||
| 92 | 26926114 |
JP |
61 | 2 |
Diarrhoea, Nausea, Ventricular tachycardia, Stress cardiomyopathy, Disease progression, |
||||
CARBOPLATIN, AFATINIB, PEMETREXED, PEMETREXED DISODIUM, DOCETAXEL, DOCETAXEL ANHYDROUS, RAMUCIRUMAB, |
||||
| 93 | 26926125 |
JP |
6 | 2 |
Disease progression, |
||||
HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, EPINEPHRINE, ADRENALINUM, MANNITOL, |
||||
| 94 | 26926126 |
JP |
4 | 2 |
Disease progression, |
||||
NOREPINEPHRINE (BITARTRATE), NOREPINEPHRINE BITARTRATE, METHYLPREDNISOLONE, MANNITOL, ASCORBIC ACID, CYANOCOBALAMIN, |
||||
| 95 | 26926128 |
EU |
34 | 1 |
Disease progression, Febrile neutropenia, |
||||
DOXORUBICIN, PREDNISONE, METHYLPREDNISOLONE, CISPLATIN, ETOPOSIDE, CYTARABINE, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BRENTUXIMAB VEDOTIN, |
||||
| 96 | 26926213 |
MX |
1 | |
Disease progression, |
||||
| 97 | 26915003 |
US |
26 | 1 |
Disease progression, Drug resistance, Metastatic neoplasm, |
||||
CISPLATIN, CARBOPLATIN, CARBOPLATIN, ETOPOSIDE, ETOPOSIDE, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, |
||||
| 98 | 26915080 |
EU |
78 | 1 |
Respiratory syncytial virus infection, Gastrointestinal disorder, Condition aggravated, Dyspnoea, Weight decreased, Apathy, Asthenia, Sarcopenia, Drug intolerance, Disease progression, |
||||
NINTEDANIB, PIRFENIDONE, |
||||
| 99 | 26915140 |
48 | 2 | |
Disease progression, Interstitial lung disease, Therapy non-responder, Off label use, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, AZATHIOPRINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, NINTEDANIB, RITUXIMAB, |
||||
| 100 | 26915222 |
EU |
||
Marginal zone lymphoma, Autoimmune haemolytic anaemia, Thrombocytopenia, Splenomegaly, Disease progression, |
||||
RITUXIMAB, RITUXIMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30